Detail (Long)
In the context of shared decision-making, clinicians may offer noninvasive therapies, pharmacotherapy, or minimally invasive therapies. [EO]<br>
◦ If OAB-predominant LUTS: bladder outlet reduction surgeries—e.g., transurethral resection, HoLEP, or photovaporization of the prostate; robotic waterjet tx; temporary implantable nitinol baskets; drug-coated balloon; water vapor thermal tx; prostatic artery embolization.<br>
◦ For procedural interventions, discuss possibility of de novo or worsening OAB sx and other adverse events—e.g., transient urge incontinence after HoLEP, worse OAB sx after photoselective vaporization of the prostate. Address persistent/de novo bothersome OAB sx after surgical tx.
◦ If OAB-predominant LUTS: bladder outlet reduction surgeries—e.g., transurethral resection, HoLEP, or photovaporization of the prostate; robotic waterjet tx; temporary implantable nitinol baskets; drug-coated balloon; water vapor thermal tx; prostatic artery embolization.<br>
◦ For procedural interventions, discuss possibility of de novo or worsening OAB sx and other adverse events—e.g., transient urge incontinence after HoLEP, worse OAB sx after photoselective vaporization of the prostate. Address persistent/de novo bothersome OAB sx after surgical tx.